• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapy and medication don't work for a majority of people suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into customized micro-interventions to improve mental health. We looked at the best ketamine treatment for depression for severe depression (her latest blog)-fitting personal ML models for each individual using Shapley values, in order to understand their features and predictors. This revealed distinct features that deterministically changed mood over time.

Predictors of Mood

depression treatment centre is one of the most prevalent causes of mental illness.1 However, only half of people suffering from the condition receive treatment1. To improve outcomes, healthcare professionals must be able to identify and treat patients who have the highest chance of responding to particular treatments.

The lithium treatment for depression of depression can be personalized to help. Utilizing sensors for mobile phones as well as an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants totaling more than $10 million will be used to determine biological and behavior predictors of response.

The majority of research conducted to the present has been focused on clinical and sociodemographic characteristics. These include demographic factors such as age, sex and education, clinical characteristics including symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data in order to predict mood in individuals. Many studies do not consider the fact that mood can differ significantly between individuals. It is therefore important to develop methods which allow for the determination and quantification of the individual differences between mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can detect different patterns of behavior and emotions that vary between individuals.

In addition to these modalities the team developed a machine-learning algorithm to model the dynamic predictors of each person's depressed mood. The algorithm combines these individual characteristics into a distinctive "digital phenotype" for each participant.

The digital phenotype was associated with CAT-DI scores, a psychometrically validated severity scale for symptom severity. However, the correlation was weak (Pearson's r = 0.08, the BH-adjusted p-value was 3.55 x 10-03) and varied widely across individuals.

Predictors of symptoms

Depression is a leading cause of disability around the world1, but it is often not properly diagnosed and treated. In addition an absence of effective interventions and stigma associated with depressive disorders prevent many people from seeking help.

To assist in individualized treatment, it is important to determine the predictors of symptoms. However, the methods used to predict symptoms rely on clinical interview, which is unreliable and only detects a small variety of characteristics related to depression.2

Machine learning is used to blend continuous digital behavioral phenotypes that are captured through smartphone sensors and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, CAT-DI) together with other predictors of symptom severity has the potential to increase the accuracy of diagnostics and the effectiveness of treatment for depression. These digital phenotypes allow continuous, high-resolution measurements as well as capture a wide range of distinct behaviors and patterns that are difficult to document through interviews.

The study included University of California Los Angeles (UCLA) students experiencing mild to severe depressive symptoms participating in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were referred to online assistance or medical care depending on the degree of their depression. Participants who scored a high on the CAT DI of 35 or 65 were allocated online support with an online peer coach, whereas those with a score of 75 patients were referred to clinics in-person for psychotherapy.

At the beginning, participants answered a series of questions about their personal demographics and psychosocial characteristics. The questions asked included education, age, sex and gender and financial status, marital status and whether they were divorced or not, their current suicidal thoughts, intentions or attempts, as well as the frequency with which they consumed alcohol. Participants also rated their degree of depression severity on a 0-100 scale using the CAT-DI. The CAT-DI test was carried out every two weeks for those who received online support, and weekly for those who received in-person support.

Predictors of Treatment Reaction

Research is focusing on personalized depression treatment. Many studies are focused on identifying predictors, which will help doctors determine the most effective drugs to treat each individual. Particularly, pharmacogenetics is able to identify genetic variants that influence how the body metabolizes antidepressants. This lets doctors select the medication that are likely to be the most effective for every patient, minimizing the amount of time and effort required for trial-and-error treatments and eliminating any adverse negative effects.

Another approach that is promising is to create prediction models combining the clinical data with neural imaging data. These models can be used to determine which variables are the most predictive of a specific outcome, such as whether a medication can help with symptoms or mood. These models can be used to determine the patient's response to a treatment, which will help doctors to maximize the effectiveness.

A new generation of studies uses machine learning methods, such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of many variables and increase predictive accuracy. These models have been demonstrated to be effective in predicting outcomes of treatment like the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to be the norm in future medical practice.

Research into the underlying causes of depression continues, as do predictive models based on ML. Recent findings suggest that depression is connected to the malfunctions of certain neural networks. This theory suggests that a individualized treatment options for depression for depression will be based upon targeted therapies that restore normal function to these circuits.

One method of doing this is by using internet-based programs which can offer an individualized and personalized experience for patients. One study found that a program on the internet was more effective than standard treatment in improving symptoms and providing a better quality of life for those suffering from MDD. Furthermore, a randomized controlled study of a customized approach to depression treatment showed sustained improvement and reduced adverse effects in a significant percentage of participants.

Predictors of Side Effects

A major challenge in personalized depression treatment involves identifying and predicting the antidepressant medications that will have minimal or no side effects. Many patients have a trial-and error method, involving a variety of medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics provides an exciting new method for an efficient and specific method of selecting antidepressant therapies.

A variety of predictors are available to determine which antidepressant to prescribe, such as gene variants, phenotypes of patients (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. However, identifying the most reliable and reliable predictors for a particular treatment is likely to require randomized controlled trials of considerably larger samples than those normally enrolled in clinical trials. This is because the identifying of interactions or moderators could be more difficult in trials that only take into account a single episode of treatment per participant instead of multiple episodes of treatment over time.

Furthermore the estimation of a patient's response to a specific medication will also likely require information about the symptom profile and comorbidities, as well as the patient's personal experiences with the effectiveness and tolerability of the medication. There are currently only a few easily measurable sociodemographic variables as well as clinical variables are reliably related to response to MDD. These include age, gender and race/ethnicity, SES, BMI and the presence of alexithymia.

There are many challenges to overcome in the application of pharmacogenetics to treat depression. First is a thorough understanding of the underlying genetic mechanisms is needed, as is a clear definition of what is a reliable predictor of treatment response. Ethics like privacy, and the ethical use of genetic information are also important to consider. Pharmacogenetics can, in the long run help reduce stigma around mental health treatment and improve treatment outcomes. However, as with any approach to psychiatry careful consideration and implementation is essential. The best course of action is to provide patients with a variety of effective depression medications and encourage them to speak with their physicians about their concerns and experiences.